Federal Circuit Denies En Banc Rehearing in Teva v. Eli Lilly, Preserving Precedent for Method-of-Treatment Patent Claims
September 30, 2026
September 30, 2026
BOSTON, Massachusetts, Sept. 30 [Category: BizLaw/Legal] -- Foley Hoag, a law firm, posted the following news:
* * *
Federal Circuit Denies En Banc Rehearing in Teva v. Eli Lilly, Preserving Precedent for Method-of-Treatment Patent Claims
*
The United States Court of Appeals for the Federal Circuit has denied Eli Lilly and Company's petition for rehearing en banc in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, No. 2024 . . .
* * *
Federal Circuit Denies En Banc Rehearing in Teva v. Eli Lilly, Preserving Precedent for Method-of-Treatment Patent Claims
*
The United States Court of Appeals for the Federal Circuit has denied Eli Lilly and Company's petition for rehearing en banc in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, No. 2024 . . .